These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Bogetto F; Bellino S; Vaschetto P; Ziero S Psychiatry Res; 2000 Oct; 96(2):91-8. PubMed ID: 11063782 [TBL] [Abstract][Full Text] [Related]
23. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E; Bianchi L; Bellodi L J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005 [TBL] [Abstract][Full Text] [Related]
25. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Hollander E; Kaplan A; Schmeidler J; Yang H; Li D; Koran LM; Barbato LM J Neuropsychiatry Clin Neurosci; 2005; 17(4):472-7. PubMed ID: 16387985 [TBL] [Abstract][Full Text] [Related]
27. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617 [TBL] [Abstract][Full Text] [Related]
28. Clinical predictors of drug response in obsessive-compulsive disorder. Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074 [TBL] [Abstract][Full Text] [Related]
29. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229 [TBL] [Abstract][Full Text] [Related]
30. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB; Gorfinkle KS; Liebowitz MR J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976 [TBL] [Abstract][Full Text] [Related]
31. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder. Yaryura-Tobias JA; Grunes MS; Walz J; Neziroglu F Int Clin Psychopharmacol; 2000 May; 15(3):163-8. PubMed ID: 10870874 [TBL] [Abstract][Full Text] [Related]
32. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. Riddle MA; Reeve EA; Yaryura-Tobias JA; Yang HM; Claghorn JL; Gaffney G; Greist JH; Holland D; McConville BJ; Pigott T; Walkup JT J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371 [TBL] [Abstract][Full Text] [Related]
33. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493 [TBL] [Abstract][Full Text] [Related]
34. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422 [TBL] [Abstract][Full Text] [Related]
35. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment. Monteleone P; Catapano F; Di Martino S; Ferraro C; Maj M Br J Psychiatry; 1997 Jun; 170():554-7. PubMed ID: 9330023 [TBL] [Abstract][Full Text] [Related]
36. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362 [TBL] [Abstract][Full Text] [Related]
37. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971 [TBL] [Abstract][Full Text] [Related]
38. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845 [TBL] [Abstract][Full Text] [Related]
39. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668 [TBL] [Abstract][Full Text] [Related]
40. Treatment of obsessive-compulsive disorder: personal follow-up of a 10-year material from an outpatient county clinic. Olsen T; Mais AH; Bilet T; Martinsen EW Nord J Psychiatry; 2008; 62(1):39-45. PubMed ID: 18389424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]